Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob Hooft van Huijsduijnen

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
The FEBS Journal|February 27, 2008
Protein tyrosine phosphatases: dual-specificity phosphatases in health and diseaseRafael Pulido, Rob Hooft van Huijsduijnen
Journal of Molecular Medicine (Berlin, Germany)|August 23, 2006
Decompartmentalizing target validation-thinking outside the pipeline boxesRob Hooft van Huijsduijnen, Christian Rommel
Methods (San Diego, Calif.)|December 14, 2004
Applying the SPOT peptide synthesis procedure to the study of protein tyrosine phosphatase substrate specificity: probing for the heavenly match in vitroXavier Espanel, Rob Hooft van Huijsduijnen
Current Opinion in Pharmacology|June 4, 2018
The antimalarial pipelineRob Hooft van Huijsduijnen, Timothy Nc Wells
Biochemical and Biophysical Research Communications|April 27, 2005
Sap-1/PTPRH activity is regulated by reversible dimerizationSébastien Wälchli, Xavier Espanel, Rob Hooft van Huijsduijnen
The Lancet. Infectious Diseases|September 7, 2015
Ferroquine: welcome to the next generation of antimalarialsTimothy N C Wells, Rob Hooft van Huijsduijnen
Drug Discovery Today|January 28, 2003
Selecting protein tyrosine phosphatases as drug targetsRob Hooft van Huijsduijnen, Agnes Bombrun, Dominique Swinnen
Protein Science : a Publication of the Protein Society|September 19, 2002
The SPOT technique as a tool for studying protein tyrosine phosphatase substrate specificitiesXavier Espanel, Martine Huguenin-Reggiani, Rob Hooft van Huijsduijnen
Malaria Journal|March 24, 2019
Two successful decades of Swiss collaborations to develop new anti-malarialsRob Hooft van Huijsduijnen, Timothy Wells, Marcel Tanner, et al.
Expert Opinion on Therapeutic Targets|December 11, 2002
Protein tyrosine phosphatases as drug targets: PTP1B and beyondRob Hooft van Huijsduijnen, Sébastien Wälchli, Mark Ibberson, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
The FEBS Journal|February 27, 2008
Protein tyrosine phosphatases: dual-specificity phosphatases in health and diseaseRafael Pulido, Rob Hooft van Huijsduijnen
Journal of Molecular Medicine (Berlin, Germany)|August 23, 2006
Decompartmentalizing target validation-thinking outside the pipeline boxesRob Hooft van Huijsduijnen, Christian Rommel
Methods (San Diego, Calif.)|December 14, 2004
Applying the SPOT peptide synthesis procedure to the study of protein tyrosine phosphatase substrate specificity: probing for the heavenly match in vitroXavier Espanel, Rob Hooft van Huijsduijnen
Current Opinion in Pharmacology|June 4, 2018
The antimalarial pipelineRob Hooft van Huijsduijnen, Timothy Nc Wells
Biochemical and Biophysical Research Communications|April 27, 2005
Sap-1/PTPRH activity is regulated by reversible dimerizationSébastien Wälchli, Xavier Espanel, Rob Hooft van Huijsduijnen
The Lancet. Infectious Diseases|September 7, 2015
Ferroquine: welcome to the next generation of antimalarialsTimothy N C Wells, Rob Hooft van Huijsduijnen
Drug Discovery Today|January 28, 2003
Selecting protein tyrosine phosphatases as drug targetsRob Hooft van Huijsduijnen, Agnes Bombrun, Dominique Swinnen
Protein Science : a Publication of the Protein Society|September 19, 2002
The SPOT technique as a tool for studying protein tyrosine phosphatase substrate specificitiesXavier Espanel, Martine Huguenin-Reggiani, Rob Hooft van Huijsduijnen
Malaria Journal|March 24, 2019
Two successful decades of Swiss collaborations to develop new anti-malarialsRob Hooft van Huijsduijnen, Timothy Wells, Marcel Tanner, et al.
Expert Opinion on Therapeutic Targets|December 11, 2002
Protein tyrosine phosphatases as drug targets: PTP1B and beyondRob Hooft van Huijsduijnen, Sébastien Wälchli, Mark Ibberson, et al.
Pageof 6